The Annals Holiday Offer - Save 50%
home help contact us subscription past issues search current issue
QUICK SEARCH:   [advanced]


     

The Annals of Pharmacotherapy: Vol. 43, No. 5, pp. 963-966. DOI 10.1345/aph.1M065
© 2009 Harvey Whitney Books Company.
This Article
Right arrow Résumé Freely available
Right arrow Extracto Freely available
Right arrow Full Text
Right arrow PDF
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Related articles in The Annals
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leeder, J S.
Right arrow Articles by Spielberg, S. P
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leeder, J S.
Right arrow Articles by Spielberg, S. P

Personalized Medicine: Reality and Reality Checks

J Steven Leeder, PharmD PhD

Marion Merrell Dow/Missouri Endowed Chair in Pediatric Pharmacology; Chief, Division of Clinical Pharmacology and Medical Toxicology; Professor of Pediatrics and Pharmacology, Children's Mercy Hospitals and Clinics, Kansas City, MO

Stephen P Spielberg, MD PhD

Marion Merrell Dow Endowed Chair in Pediatric Pharmacogenomics; Director, Center for Personalized Medicine and Therapeutic Innovation; Professor of Pediatrics, Children's Mercy Hospitals and Clinics

Reprints: Dr. Leeder, Division of Clinical Pharmacology and Medical Toxicology, Children's Mercy Hospitals and Clinics, 2401 Gillham Rd., Kansas City, MO 64108, fax 816/855-1958, sleeder{at}cmh.edu

Abstract

The evolving era of pharmacogenomics and personalized medicine is greeted with optimism by many, but this sentiment is not universally shared. The existence of diametrically opposed opinions concerning the potential benefits and obstacles facing the widespread implementation of genomic medicine should stimulate discussion and guide the design of studies to establish the value of interventions targeted at the level of individual patients. One of the more controversial aspects of personalized medicine is whether the anticipated benefits will be realized at an acceptable cost. Recently released analyses suggest that the returns on investment depend on the particular scenario and are different for different stakeholders. On the other hand, cost is only one of the challenges regarding implementation of personalized medicine. Among these are the development of universal standards for managing genomic information in electronic medical records, improvement in the collection and interpretation of clinical phenotype data, and new strategies to educate practitioners and patients/consumers. The reality is that personalized medicine is upon us; open discourse and periodic reality checks will be necessary as we confront it.

Key Words: cost-benefit analysis, personalized medicine, pharmacogenomics

Published Online, May 5, 2009. www.theannals.com, DOI 10.1345/aph.1M065

Related articles in The Annals:

Personalized Medicine: Boon or Budget-Buster?
Charles E Dean
The Annals 2009 43: 958-962. [Abstract] [Full Text]  





homecopy help contact us subscription past issues search current issue
Copyright © 2009 by Harvey Whitney Books Company.